COVID-19 during Pregnancy and Postpartum: Antiviral Spectrum of Maternal Lactoferrin in Fetal and Neonatal Defense

Sreus A. G. Naidu et al - Journal of Dietary Supplements 16 Nov 2020

 

As the COVID-19 pandemic intensified the global health crisis, the containment of SARS-CoV-2 infection in pregnancies, and the inherent risk of vertical transmission of virus from mother-to-fetus (or neonate) poses a major concern. Most COVID-19-Pregnancy patients showed mild to moderate COVID-19 pneumonia with no pregnancy loss and no congenital transmission of the virus; however, an increase in hypoxia-induced preterm deliveries was apparent. Also, the breastmilk of several mothers with COVID-19 tested negative for the virus.

Taken together, the natural barrier function during pregnancy and postpartum seems to deter the SARS-CoV-2 transmission from mother-to-child. This clinical observation warrants to explore the maternal-fetal interface and identify the innate defense factors for prevention and control of COVID-19-Pregnancy. Lactoferrin (LF) is a potent antiviral iron-binding protein present in the maternal-fetal interface. In concert with immune co-factors, maternal-LF modulates chemokine release and lymphocyte migration and amplify host defense during pregnancy.

LF levels during pregnancy may resolve hypertension via down-regulation of ACE2; consequently, may limit the membrane receptor access to SARS-CoV-2 for cellular entry. Furthermore, an LF-derived peptide (LRPVAA) has been shown to block ACE receptor activity in vitro. LF may also reduce viral docking and entry into host cells and limit the early phase of COVID-19 infection. An in-depth understanding of LF and other soluble mammalian milk-derived innate antiviral factors may provide insights to reduce co-morbidities and vertical transmission of SARS-CoV-2 infection and may lead to the development of effective nutraceutical supplements.

https://www.tandfonline.com/doi/full/10.1080/19390211.2020.1834047

More about lactoferrin:

Lactoferrin as potential preventative and treatment for COVID-19

 Lactoferrin as Protective Natural Barrier of Respiratory and Intestinal Mucosa against Coronavirus Infection and Inflammation

Una risposta contro il Covid-19: la glicoproteina lattoferrina, una componente dell’immunità innata

 

 

 

Ultima modifica il Lunedì, 16 Novembre 2020 10:55
Vota questo articolo
(0 Voti)

Lascia un commento

Assicurati di aver digitato tutte le informazioni richieste, evidenziate da un asterisco (*). Non è consentito codice HTML.

 

Scienzaonline con sottotitolo Sciencenew  - Periodico
Autorizzazioni del Tribunale di Roma – diffusioni:
telematica quotidiana 229/2006 del 08/06/2006
mensile per mezzo stampa 293/2003 del 07/07/2003
Scienceonline, Autorizzazione del Tribunale di Roma 228/2006 del 29/05/06
Pubblicato a Roma – Via A. De Viti de Marco, 50 – Direttore Responsabile Guido Donati

Photo Gallery